All Stories

  1. The recent rapid expansion of multidrug resistant Ural lineage Mycobacterium tuberculosis in Moldova
  2. Identifying local foci of tuberculosis transmission in Moldova using a spatial multinomial logistic regression model
  3. Identification of differentially recognized T cell epitopes in the spectrum of tuberculosis infection
  4. Predicting stringent QuantiFERON-TB Gold Plus conversions in contacts of tuberculosis patients
  5. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis: a mathematical modeling analysis
  6. Geographical analysis and evaluation of M. tuberculosis genome sequencing at the national level
  7. Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis
  8. Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis using machine learning methods
  9. Phylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis
  10. Integrating landmark modeling framework and machine learning algorithms for dynamic prediction of tuberculosis treatment outcomes
  11. Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study
  12. Benchmarking the empirical accuracy of short-read sequencing across the M. tuberculosis genome
  13. Emergence of bedaquiline-resistance in a high-burden country of tuberculosis
  14. Evolution and emergence of multidrug-resistant Mycobacterium tuberculosis in Chisinau, Moldova
  15. Rapid Detection of Extensively Drug-Resistant Tuberculosis in Clinical Samples Using a Novel Tabletop Platform: Protocol for a Prospective Clinical Study
  16. Phylogeography and transmission of M. tuberculosis in Moldova
  17. Clinical evaluation of the Xpert MTB/XDR assay for rapid detection of isoniazid, fluoroquinolone, ethionamide and second-line drug resistance: A cross-sectional multicentre diagnostic accuracy study
  18. Genomic sequence characteristics and the empiric accuracy of short-read sequencing
  19. Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting
  20. Evolution and emergence of multidrug-resistant Mycobacterium tuberculosis in Chisinau, Moldova
  21. Rapid Detection of Extensively Drug-Resistant Tuberculosis in Clinical Samples Using a Novel Tabletop Platform: Protocol for a Prospective Clinical Study (Preprint)
  22. Molecular Detection of Mycobacterium tuberculosis in Oral Mucosa from Patients with Presumptive Tuberculosis
  23. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country
  24. Automated high-throughput digital fluorescence microscopy for TB diagnosis
  25. A retrospective genomic analysis of drug-resistant strains of M. tuberculosis in a high-burden setting, with an emphasis on comparative diagnostics and reactivation and reinfection status
  26. A retrospective genomic analysis of drug-resistant strains of M. tuberculosis in a high-burden setting, with an emphasis on comparative diagnostics and reactivation and reinfection status.
  27. Prediction of multiple drug resistant pulmonary tuberculosis against drug sensitive pulmonary tuberculosis by CT nodular consolidation sign
  28. Assessing tuberculosis control priorities in high-burden settings: a modelling approach
  29. Failing treatment of multidrug-resistant tuberculosis: a matter of definition
  30. Building a tuberculosis-free world: The Lancet Commission on tuberculosis
  31. Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: systematic review and meta-analysis
  32. Beyond the SNP Threshold: Identifying Outbreak Clusters Using Inferred Transmissions
  33. Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries
  34. Beyond the SNP threshold: identifying outbreak clusters using inferred transmissions
  35. Cost analysis of rapid diagnostics for drug-resistant tuberculosis
  36. Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria
  37. Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure
  38. High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova
  39. Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of thekatG315T mutation
  40. The TB Portals: database for M/XDR TB
  41. Treatment outcomes of MDR-TB and HIV co-infection in Europe
  42. FATE: the new partnership to Fight Against TB in Central and Eastern Europe
  43. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance
  44. MDR-TB in Eastern Europe in the era of the TB elimination action framework
  45. Armed conflict and population displacement as drivers of the evolution and dispersal of Mycobacterium tuberculosis
  46. Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages
  47. Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe
  48. Urgent need to rethink treatment outcome definitions in tuberculosis
  49. Shedding light on the performance of a pyrosequencing assay for drug-resistant tuberculosis diagnosis
  50. Errata
  51. Rapid Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study
  52. A performance evaluation of MTBDRplus version 2 for the diagnosis of multidrug-resistant tuberculosis
  53. Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape
  54. In reply
  55. MTBDRplusand MTBDRslAssays: Absence of Wild-Type Probe Hybridization and Implications for Detection of Drug-Resistant Tuberculosis
  56. Nosocomial transmission of multidrug-resistant tuberculosis
  57. Beyond multidrug-resistant tuberculosis in Europe: a TBNET study
  58. Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations
  59. Out-patient MDR-TB care in Moldova
  60. Transmission ofmycobacterium tuberculosisUral 163-15 lineage causing multidrug-resistant tuberculosis among hospitalized patients
  61. Performance Comparison of Three Rapid Tests for the Diagnosis of Drug-Resistant Tuberculosis
  62. Detection of Low-Level Mixed-Population Drug Resistance in Mycobacterium tuberculosis Using High Fidelity Amplicon Sequencing
  63. Phenotypic and genotypic diversity in a multinational sample of drug-resistant Mycobacterium tuberculosis isolates
  64. Combined Antigen-Specific Interferon-γ and Interleukin-2 Release Assay (FluoroSpot) for the Diagnosis of Mycobacterium tuberculosis Infection
  65. Multidrug-Resistant Tuberculosis in Europe, 2010–2011
  66. Prognostic significance of novel katG mutations in Mycobacterium tuberculosis
  67. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage
  68. Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates
  69. The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis
  70. Evaluation of Pyrosequencing for Detecting Extensively Drug-Resistant Mycobacterium tuberculosis among Clinical Isolates from Four High-Burden Countries
  71. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement
  72. High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova
  73. Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay
  74. Predicting Extensively Drug-Resistant Mycobacterium tuberculosis Phenotypes with Genetic Mutations
  75. Publisher's Expression of Concern: Geographical Differences Associated with SNPs in Nine Gene Targets among Resistant Clinical Isolates of Mycobacterium tuberculosis
  76. Geographical Differences Associated with Single-Nucleotide Polymorphisms (SNPs) in Nine Gene Targets among Resistant Clinical Isolates of Mycobacterium tuberculosis
  77. Risk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova
  78. Periodontal Disease Is an Independent Predictor of Intracardiac Calcification
  79. Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country
  80. Middle‐of‐the‐night PCI does not affect subsequent day PCI success and complication rates by the same operator
  81. First Evaluation of an Improved Assay for Molecular Genetic Detection of Tuberculosis as Well as Rifampin and Isoniazid Resistances
  82. Complications related to access site after percutaneous coronary interventions
  83. Can total cardiac calcium predict the coronary calcium score?
  84. Assessment Of The Nosocomial Transmission Of MDR TB In Moldova Using DNA Fingerprinting Of M.tuberculosis
  85. Relationship between intensive diuresis and QRS morphology change
  86. Increasing tuberculosis case detection: lessons from the Republic of Moldova